 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| REGN5713-5715 / Regeneron
New P3 trial: A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy (clinicaltrials.gov) - Sep 19, 2024
P3, N=50, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||| REGN5713-5715 / Regeneron, REGN5715 / Regeneron, REGN5713-5714-5715 / Regeneron
Trial completion: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - Aug 16, 2023
P2, N=218, Completed, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed
- ||| REGN5713-5715 / Regeneron, REGN5715 / Regeneron, REGN5713-5714-5715 / Regeneron
Enrollment closed: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - Apr 27, 2023
P2, N=218, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| REGN5713-5715 / Regeneron, REGN5715 / Regeneron, REGN5713-5714-5715 / Regeneron
Enrollment open: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - Oct 17, 2022
P2, N=300, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| REGN5713-5715 / Regeneron, REGN5715 / Regeneron, REGN5713-5714-5715 / Regeneron
New P2 trial: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants (clinicaltrials.gov) - Jun 23, 2022
P2, N=300, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- Efficacy of Anti-Allergen Therapeutics in a Preclinical Model of Allergic Anaphylaxis Correlates with Symptomatic Relief in Allergic Patients () - Apr 30, 2022 - Abstract #EAACI2022EAACI_998;
Blockade of individual mAbs versus mAb cocktails confirms optimal blocking efficacy of Fel d 1 mAb cocktail (REGN1908-1909) compared with either single mAb; Bet v 1 triple mAb cocktail (REGN5713-5714-5715) compared with single mAb (REGN5715) or dual mAb cocktail (REGN5713-5715). Conclusion Blockade of mast cell degranulation in the PCA mouse model correlates to efficacy in clinical settings, validating the model as a useful tool for selection of efficacious anti-allergen therapeutics.